Impact Biomedical (IBO) Notes Payables (2022 - 2025)

Impact Biomedical (IBO) has reported Notes Payables for 4 consecutive years, with $22.9 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Notes Payables rose 65274.29% year-over-year to $22.9 million; the trailing twelve-month figure through Sep 2025 stood at $22.9 million (up 65274.29% YoY), and the FY2024 full-year result was $8.9 million, down 26.47% from the prior year.
• Notes Payables advanced to $22.9 million in Q3 2025 per IBO's latest filing, from $22.4 million in the prior quarter.
• Across five years, Notes Payables topped out at $22.9 million in Q3 2025 and bottomed at $35000.0 in Q3 2024.
• Historically, Notes Payables has averaged $12.3 million across 4 years, with a median of $11.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Notes Payables plunged 99.7% in 2024, then soared 65274.29% in 2025.
• Over 4 years, Notes Payables stood at $10.0 million in 2022, then gained by 20.85% to $12.1 million in 2023, then decreased by 26.47% to $8.9 million in 2024, then surged by 157.73% to $22.9 million in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $22.9 million, $22.4 million, and $9.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.